MSD - Latest News [Page 1]
(MSD) Welcomes News That Pharmac Is Proposing To Fund KEYTRUDA® (pembrolizumab) For 5 Additional Cancer Types
Saturday, 6 July 2024, 4:49 am | MSD
Merck Sharp & Dohme (New Zealand) Limited (MSD) welcomes news that Pharmac is consulting on a funding proposal for KEYTRUDA® (pembrolizumab) for five additional types of cancer. More >>
MSD says thanks to its New Zealand Clinical Trial Patients
Tuesday, 28 May 2019, 11:49 am | MSD
28th May 2019. In acknowledgement of International Clinical Trials Day, MSD wants to say thank you to the 500 MSD clinical trial patients around the country.1 More >>
KEYTRUDA® registered for treatment of lung cancer
Friday, 21 April 2017, 12:43 pm | MSD
April 20, 2017, Merck Sharp & Dohme Limited (MSD) today announced KEYTRUDA® (pembrolizumab) has now received its second Medsafe registration for lung cancer. More >>
KEYTRUDA funded for melanoma, new indications in process
Tuesday, 2 August 2016, 2:31 pm | MSD
MSD is pleased that PHARMAC has announced it will fund anti-PD1 immunotherapy medicine KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma that has spread through the body – effective from September 1. Mr Paul Smith, MSD New Zealand Director, ... More >>
MSD signs KEYTRUDA agreement and offers bridging programme
Tuesday, 28 June 2016, 3:51 pm | MSD
MSD has signed a provisional agreement with PHARMAC (subject to stakeholder consultation and PHARMAC board approval) to fund MSD’s anti-PD1 immunotherapy KEYTRUDA® (pembrolizumab) for the treatment of advanced melanoma that has spread. Mr Paul Smith, MSD New Zealand ... More >>
Covering risk from abortion losses
Tuesday, 2 February 2016, 1:24 pm | MSD
Losing healthy sets of twins through abortion when you’ve worked so hard to get them safely to this point is “heart-breaking”, says Southland farmer Shane Roy. More >>
New Zealand Doctors Can Now Access Univadis®
Monday, 3 August 2015, 11:41 am | MSD
New Zealand doctors now have access to Univadis, a free medical education and unbiased health information website for healthcare professionals. More >>
Funded Gastroenteritis Vaccine for Babies Nearly Here!
Tuesday, 24 June 2014, 12:18 pm | MSD
Soon babies born in New Zealand will be eligible for funded vaccination against rotavirus gastroenteritis caused by rotavirus infection. PHARMAC has funded ROTATEQ® (rotavirus vaccine, live, oral, pentavalent) and added it to the Immunisation Schedule from ... More >>
New Zealanders flock to get shingles vaccine
Monday, 9 June 2014, 1:00 pm | MSD
New Zealanders have flocked to surgeries in recent months to get the world’s first and only vaccine, ZOSTAVAX™, that helps protect against the acute and chronic pain of shingles. Shingles affects up to 1 in 3 people, who have had chickenpox, during ... More >>
NZ Women Now Have Access to New Once Monthly Vaginal Ring
Tuesday, 3 December 2013, 2:27 pm | MSD
For women who don’t want the hassle of a daily contraceptive, there is now a new once monthly contraception option - NuvaRing® (120mcg etonogestrel / 15mcg ethinyl estradiol per day). More >>